Continuing Medical EdUcation (CME)


The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


AACR has designated this live activity for a maximum of 23.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey (available in September) by Wednesday, November 14, 2018. Certificates will only be issued to those who complete the survey.  Your CME certificate will be sent to you via email after the completion of the activity.


An estimated 1,735,350 new cancer cases will be diagnosed in 2018 in the United States, and 609,640 people will die from the disease. Continued efforts are needed to identify new strategies and therapeutic options to improve patient survival and quality of life.

Immunotherapy is a promising area that takes advantage of the body’s natural defenses to fight cancer.  Scientists are discovering novel therapeutic strategies to harness the power of the immune system to specifically target tumor cells or to counteract immunosuppressive signals for improved regression and complete remission for cancer patients. New technologies have greatly enhanced our understanding of immune surveillance, vastly contributing to the development of novel immunotherapies. To further improve the prognosis and outcome of subsequent therapies, it is extremely important to understand the interaction of tumor cells with their microenvironment.  Adoptive cell therapy (ACT) continues to gain traction, and chimeric antigen receptor (CAR)-modified T cells have shown clinical successes in hematopoietic malignancies.  Cancer vaccines are also being developed to both treat and prevent certain cancers. Monoclonal antibodies and checkpoint inhibitors are being used to fight many types of cancer, with 25 monoclonal antibodies and 6 checkpoint inhibitors approved by the FDA. Combination and targeted therapies are promising and active areas of research as researchers learn how to predict an individual’s response to treatment. Importantly, as individualized therapy becomes more prevalent, researchers and physicians can utilize technology – to analyze and alter single cells – to aid more patients, faster.

To develop more effective therapies for a broader range of cancer types, it is essential to provide a venue for researchers, physician scientists, and all stakeholders to meet, share novel findings, and have an active exchange of ideas.  This joint meeting will provide an unparalleled opportunity for teaching, learning, and networking. The potential of immune-based therapeutics will be fully explored, and successes in clinical trials and clinical trial design will be discussed.  This conference will stimulate discussions and an active exchange of scientific ideas for the development of more effective therapies for a broader range of cancer types.

After participating in this CME activity, physicians should be able to:

  • Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs.

  • Articulate how checkpoint blockade is being used in a therapeutic setting.

  • Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth.

  • Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy.

  • Identify mechanisms involved in the biology of vaccination.

  • Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy.

  • Utilize technology to aid in cancer cell characterization and immunotherapy.


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.


This activity is supported by grants and will be disclosed at the activity. 


Please contact the Office of CME at (215) 440-9300 or